ReWalk Robotics Reports First Quarter 2015 Financial Results YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA

ReWalk Robotics Reports First Quarter

2015 Financial Results

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, May 7, 2015 -

ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial results for

the three months ended March 31, 2015.

Highlights of and subsequent to the first quarter include:

"Sales this quarter were less than expected

as the number of units placed were impacted by longer cycle times to complete patient evaluation, training, and processing of reimbursement

claims," said Larry Jasinski, Chief Executive Officer.

"During the quarter we made excellent

progress in building our overall training infrastructure, expanding market awareness and creating a high level of qualified customer

demand. Due to stronger customer interest, we are now directing more qualified leads to our training centers, which we believe

will result in higher sales. April commitments are already equal to first quarter sales, and we have two months remaining in Q2.

Our outlook remains positive for growth over the course of the year," he added.

"Our strategic plan for initial case-by-case

reimbursement along with parallel long-term activities is the key to achieving our overall growth targets. The experienced reimbursement

team we have recruited has begun to build the infrastructure we need to enable more individuals to obtain coverage for their systems

in the short term and will be able to support market growth over the next few years." Jasinski concluded.

First Quarter 2015 Financial Results

Total revenue was $635,000 for the

first quarter of 2015, up 43% compared with $445,000 in the first quarter of 2014, due to higher placements of ReWalk systems during

the first quarter of 2015. In the first quarter of 2015, 13 ReWalk systems were placed compared with six ReWalk systems placed

in the prior year period.

Gross profit for the first quarter of 2015

was $33,000 as compared to a gross loss of $0.2 million in the first quarter of 2014. This was largely due to the positive impact

of moving manufacturing operations to Sanmina in the second half of 2014.

Total operating expenses in the first quarter

of 2015 were $5.6 million, compared with $2.8 million in the first quarter of 2014, and reflects the Company's increased

investment in sales, marketing, and research and development resources and the increased cost of being a publicly-traded company.

Net loss was $5.7 million for the first

quarter of 2015 compared with $5.1 million in the prior year quarter. Non-GAAP net loss for the first quarter of 2015 was $5.1

million compared with non-GAAP net loss of $2.9 million in the prior year quarter.

A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

As of March 31, 2015, ReWalk had $37 million

in cash and cash equivalents.

The Company is providing top-line guidance

of $7 million to $10 million for 2015 based on its anticipated sales ramp for the ReWalk system.

ReWalk management will host its third

quarter conference call as follows:

A telephone replay will be available shortly

after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode for the

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally

change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the

U.S., Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

Forward Looking Statements

This press release contains forward-looking

information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking

statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"

"will," "may," "intends," "anticipate(s)," "look forward," "upcoming,"

"plan," "enables," "potentially," "entitles," and similar expressions are intended

to identify forward-looking statements. These statements include, but are not limited to, statements regarding the anticipated

revenues and underlying sales for the first quarter and fiscal 2015; future availability of reimbursement for ReWalk in Germany

and the United States; and the successful and timely achievement of favorable coverage decisions for ReWalk by additional major

insurers. All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and

generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied

or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to

the following: the market for medical exoskeletons is new and unproven, and important assumptions about the potential market for

our products may be inaccurate; the Company has a limited operating history upon which you can evaluate our business plan and prospects;

if we are unable to expand our sales, marketing and training infrastructure, we may fail to increase our sales; the health benefits

of ReWalk have not been substantiated by long-term clinical data, which could limit sales; the Company may fail to secure or retain

adequate coverage or reimbursement for ReWalk by third-party payers; the Company depends on a single third-party to manufacture

ReWalk and a limited number of third-party suppliers for certain components of ReWalk; the Company's future growth and operating

results will depend on our ability to develop and commercialize new products and penetrate new markets; the Company operates in

a competitive industry that is subject to rapid technological change, and we expect competition to increase; and the Company is

subject to extensive governmental regulations relating to the manufacturing, labeling and marketing of our products. These

and other risk factors are set forth in the Company's final Annual Report on Form 20-F for the year-ended December 31, 2014

filed with the Securities and Exchange Commission on February 27, 2015, and our other reports filed from time to time with the

Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements

that speak only as of the date hereof. ReWalk does not undertake any obligation to revise and disseminate forward-looking

statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

ReWalk is a registered trademark of

ReWalk Robotics Ltd. in Israel.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which

are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use

of non-GAAP accounting measures, including non-GAAP net loss is helpful to its investors. These measures, which the Company refers

to as our non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three-months ended March 31, 2015 and 2014, non-GAAP

net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense and (ii) the revaluation

of warrants to purchase convertible preferred shares.

Because of varying available valuation methodologies, subjective

assumptions, and the variety of equity instruments that can impact a company's non-cash expenses, the Company believes that

providing non-GAAP financial measures that exclude share-based compensation expense and non-cash financial (income) expenses allow

for more meaningful comparisons between our operating results from period to period. Each of our non-GAAP financial measures is

an important tool for financial and operational decision-making and for evaluating our own operating results over different periods

of time. The non-GAAP financial data are not measures of our financial performance under U.S. GAAP, and should not be considered

as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial

measures may not provide information that is directly comparable to that provided by other companies in our industry, as other

companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual

items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not

prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses

that may have a material impact on our reported financial results. Further, share-based compensation expense has been, and will

continue to be for the foreseeable future, a significant recurring expense in our business and an important part of the compensation

provided to our employees. The presentation of non-GAAP financial information is not meant to be considered in isolation or as